Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn’s disease: an open-label, pilot study

Techniques in Coloproctology

Volumn 18, Issue 11, 2014, Pages 1041-1046

  Tursi, A ^a   Elisei, W ^b   Picchio, M ^c   Zampaletta, C ^d   Pelecca, G ^d   Faggiani, R ^d   Brandimarte, G ^e  

^a ASL BAT   (Italy)

^b ASL RMH   (Italy)

^c Department of Surgery Hospital P Colombo   (Italy)

^d BELCOLLE HOSPITAL   (Italy)

^e Cristo Re Hospital   (Italy)

Author keywords

Adalimumab; Crohn s disease; Infliximab; Postoperative recurrence

Indexed keywords

ADALIMUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COLON BIOPSY; COLON RESECTION; CONTROLLED STUDY; CROHN DISEASE; DISEASE CONTROL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; OUTCOME ASSESSMENT; PILOT STUDY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; TREATMENT INDICATION; YOUNG ADULT; ABDOMINAL SURGERY; ANTAGONISTS AND INHIBITORS; BIOPSY; DIGESTIVE TRACT ENDOSCOPY; DOSE RESPONSE; FOLLOW UP; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; CROHN DISEASE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSCOPY, DIGESTIVE SYSTEM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; PILOT PROJECTS; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84919392868     PISSN: 11236337     EISSN: 1128045X     Source Type: Journal    
DOI: 10.1007/s10151-014-1177-1     Document Type: Article

References (39)

1. Loftus EV, Schoenfeld P, Sandborn WJ (2002) The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 16:51–60
2. Jess T, Riis L, Vind I et al (2007) Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 13:481–489
3. Nos P, Domenech E (2008) Postoperative Crohn’s disease recurrence: a practical approach. World J Gastroenterol 14:5540–5548
4. Olaison G, Smedh K, Sjodahl R (1992) Natural course of Crohn’s disease after ileocolic resection: endoscopically visualized ileal ulcers preceding symptoms. Gut 33:331–335
5. Rutgeerts P, Geboes K, Vantrappen G et al (1990) Predictability of the postoperative course of Crohn’s disease. Gastroenterology 99:956–963
6. Van Assche G, Dignass A, Reinisch W et al (2010) The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis 4:63–101
7. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP (2008) The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis 23:1213–2121
8. Simillis C, Yamamoto T, Reese GE et al (2008) A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn’s disease. Am J Gastroenterol 103:196–205
9. Hofer B, Böttger T, Hernandez-Richter T, Seifert JK, Junginger T (2001) The impact of clinical types of disease manifestation on the risk of early postoperative recurrence in Crohn’s disease. Hepatogastroenterology 48:152–155
10. Sachar DB, Lemmer E, Ibrahim C et al (2009) Recurrence patterns after first resection for structuring or penetrating Crohn’s disease. Inflamm Bowel Dis 15:1071–1075
11. Parente F, Sampietro GM, Molteni M et al (2004) Behaviour of the bowel wall during the first year after surgery is a strong predictor of symptomatic recurrence of Crohn’s disease: a prospective study. Aliment Pharmacol Ther 20:959–968
12. Hellers G (1979) Crohn’s disease in Stockholm county 1955–1974. A study of epidemiology, results of surgical treatment and long-term prognosis. Acta Chir Scand Suppl 490:1–84
13. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC (2009) Interventions for prevention of post-operative recurrence of Crohn’s disease. Cochrane Database Syst Rev 7:CD006873
14. Ford AC, Kane SV, Khan KJ et al (2011) Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol 106:617–629
15. Caprilli R, Andreoli A, Capurso L et al (1994) Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn’s disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 8:35–43
16. Florent C, Cortot A, Quandale P et al (1996) Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn’s disease. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Eur J Gastroenterol Hepatol 8:229–233
17. Rutgeerts P, Hiele M, Geboes K et al (1995) Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 108:1617–1621
18. Rutgeerts P, Van Assche G, Vermeire S et al (2005) Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128:856–861
19. Hanauer SB, Korelitz BI, Rutgeerts P et al (2004) Post-operative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine or placebo: a 2 year trial. Gastroenterology 127:723–729
20. D’Haens GR, Vermeire S, Van Assche G et al (2008) Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology 135:1123–1129
21. Reinisch W, Angelberger S, Petritsch W et al (2010) Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn’s disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 59:752–759
22. Regueiro M, Schraut W, Baidoo L et al (2009) Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 136:441–450
23. Armuzzi A, Felice C, Papa A et al (2013) Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn’s disease: an open-label pilot study. J Crohns Colitis 7:e623–e629
24. Aguas M, Bastida G, Cerrillo E et al (2012) Adalimumab in prevention of postoperative recurrence of Crohn’s disease in high-risk patients. World J Gastroenterol 18:4391–4398
25. Papamichael K, Archavlis E, Lariou C, Mantzaris GJ (2012) Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn’s disease: a prospective, two-year, single center, pilot study. J Crohns Colitis 6:924–931
26. De Cruz P, Kamm MA, Hamilton AL et al (2012) Adalimumab prevents post-operative Crohn’s disease recurrence, and is superior to thiopurines: early results from the POCER study. Gastroenterology 142:S212
27. Harvey RF, Bradshaw JM (1980) A simple index of Crohn’s disease activity. Gut 1:514
28. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R (2000) A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47:404–409
29. Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L (2012) Review article: the natural history of postoperative Crohn’s disease recurrence. Aliment Pharmacol Ther 35:625–633
30. Buisson A, Chevaux JB, Bommelaer G, Peyrin-Biroulet L (2012) Diagnosis, prevention and treatment of postoperative Crohn’s disease recurrence. Dig Liver Dis 44:453–460
31. Peyrin-Biroulet L, Deltenre P, Ardizzone S et al (2009) Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol 104:2089–2096
32. Ardizzone S, Maconi G, Sampietro GM et al (2004) Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology 127:730–737
33. Sorrentino D, Terrosu G, Avellini C, Maiero S (2007) Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn’s disease. Arch Intern Med 167:1804–1807
34. Savarino E, Bodini G, Dulbecco P et al (2013) Adalimumab is more effective than azathioprine and mesalamine at prevention of postoperative recurrence of Crohn’s disease: a randomized controlled trial. Am J Gastroenterol 108:1731–1742
35. Best WR, Becktel JM, Singleton JW, Kern F Jr (1979) Development of a Crohn’s disease activity index. Gastroenterology 70:439–444
36. Tursi A (2001) Delayed orocecal transit time and bacterial overgrowth in Crohn’s disease. J Clin Gastroenterol 32:274–275
37. Moran G, Kaplan G, Yang H et al (2012) Inflammatory uncomplicated phenotype at the start of biological therapy predicts best surgery-free outcomes. J Crohns Colitis 6(Suppl 1):S137
38. Ahmed T, Rieder F, Fiocchi C, Achkar JP (2011) Pathogenesis of postoperative recurrence in Crohn’s disease. Gut 60:553–652
39. Yoshida K, Fukunaga K, Ikeuchi H et al (2012) Scheduled infliximab monotherapy to prevent recurrence of Crohn’s disease following ileocolonic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis 18:1617–1623